Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Raman, Jaishree ^a   Mauff, Katya ^b   Muianga, Pedro ^c   Mussa, Abdul ^d   Maharaj, Rajendra ^a   Barnes, Karen I ^b  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Gaza Province Directorate of Health   (Mozambique)

^d National Malaria Control Programme   (Mozambique)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE PLUS SULFADOXINE PYRIMETHAMINE; CARRIER PROTEIN; CHLOROQUINE; CHLOROQUINE RESISTANCE TRANSPORTER; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; ARTEMISININ DERIVATIVE;

ADOLESCENT; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; COPY NUMBER VARIATION; CRT GENE; DHFR GENE; DHPS GENE; DRUG EFFICACY; DRUG LEGISLATION; GENE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MDR1 GENE; MOZAMBIQUE; NONHUMAN; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PREVALENCE; RISK REDUCTION; SCHOOL CHILD; ALLELE; ANIMAL; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; GENETICS; GEOGRAPHY; HEALTH SURVEY; MUTATION; PARASITE; PARASITOLOGY;

ARTESUNATE; PLASMODIUM FALCIPARUM;

ADOLESCENT; ALLELES; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GEOGRAPHY; HUMANS; MALARIA; MOZAMBIQUE; MUTATION; PARASITES; POPULATION SURVEILLANCE;

EID: 80054692859     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025992     Document Type: Article

References (33)

1. WHO (2010) Malaria World Report 2010, Available: http://www.who.int/malaria/publications/atoz/9789241564106/en/index.html. Accessed 2011 Sep 12.
2. WHO (2010) Global Report on Antimalarial Drug Efficacy and Drug Resistance 2000-2010, Available: http://www.who.int/malaria/publications/atoz/9789241500479/en/index.html. Accessed 2011 Jul 14.
3. WHO (2003) Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Available: http://www.int/malaria/publications/atoz/whohtmrbm200350/en/. Accessed 2011 Sep 19.
4. White NJ, (1999) Antimalarial drug resistance and chemotherapy. Philos Trans R Soc Lond B Biol Sci 354: 739-749.
5. White NJ, (2008) How antimalarial drug resistance affects post-treatment prophylaxis. Malar J 7: 9.
6. Djimde AA, Fofana B, Sagara I, Sidibe B, Toure S, et al. (2008) Efficacy, safety and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg 78: 455-461.
7. Raman J, Little F, Roper C, Kleinschmidt I, Cassim Y, et al. (2010) Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. Am J Trop Med Hyg 82: 788-794.
8. Sharp BL, Kleinschmidt I, Streat E, Maharaj R, Barnes KI, et al. (2007) Seven years of regional malaria control collaboration - Mozambique, South African and Swaziland. Am J Trop Med Hyg 76: 42-47.
9. Raman J, Sharp B, Kleinschmidt I, Roper C, Streat E, et al. (2008) Differential effect of regional drug pressure on dihydrofolate reductase and dihydrosynthetase mutations in southern Mozambique. Am J Trop Med Hyg 78: 256-261.
10. Enosse S, Magnussen P, Abacassamo F, Gomez-Olive X, Ronn AM, et al. (2008) Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotyes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. Malar J 7: 115.
11. Wooden J, Keyes S, Sibley CH, (1993) PCR and Strain Identification in Plasmodium falciparum. Parasitol Today 9: 303-305.
12. Mangold KA, Manson RU, Koay ESC, Stephens L, Regner M, et al. (2005) Real Time PCR for Detection and Identification of Plasmodium spp. J Clin Microbiol 43: 2435-2440.
13. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, et al. (1997) Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 176: 1590-1596.
14. Djimde AA, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, et al. (2001) A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 343: 257-263.
15. Sutherland CJ, Haustein T, Gadalla N, Armstrong M, Doherty JF, et al. (2007) Chloroquine-resistant Plasmodium falciparum infections among UK travellers returning with malaria after chloroquine prophylaxis. J Antimicrobial Chem 59: 1197-1199.
16. Price RN, Uhlemann A-C, Brockman A, McGready R, Ashley E, et al. (2004) Mefloquine resistance in Plasmodium falciparum and increased pdmfr1 gene copy number. Lancet 364: 438-447.
17. Menard D, Yapou A, Manirakiza A, Djalle D, Matsika-Claquin MD, et al. (2006) Polymorphisms in PFCRT, PFMDR1, DHFR genes and in vitro responses to antimalarials in Plasmodium falciparum isolates from Bangui, Central African Republic. Am J Trop Med Hyg 75: 381-387.
18. Roper C, Pearce R, Bredenkamp B, Gumede J, Drakeley C, et al. (2003) Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 361: 1174-1181.
19. Roper C, Pearce R, Nair S, Sharp B, Nosten F, et al. (2004) Intercontinental spread of pyrimethamine-resistant malaria. Science 305: 1124-1124.
20. Allen EN, Little F, Camba T, Cassam Y, Raman J, et al. (2009) Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomised controlled trial. Malar J 8: 141.
21. White NJ, (2004) Antimalarial drug resistance. J Clin Invest 113: 1084-1092.
22. Kublin JG, Cortese JF, Njunju EM, Makadam RAG, Wirima JJ, et al. (2003) Re-emergence of chloroquine sensitive Plasmodium falciparum malaria after the cessation of chloroquine use in Malawi. J Infect Dis 187: 1870-1875.
23. Sisowath C, Ferreira PE, Bustamante LY, Dahlstrom S, Martensson A, et al. (2007) The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health 12: 736-742.
24. Lopes D, Rungsihirunrat K, Nogueira F, Seugorn A, Gil JP, et al. (2002) Molecular characterisation of drug resistant Plasmodium falciparum from Thailand. Malar J 1: 12.
25. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Rinder M, et al. (2000) The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anitmalarials mefloquine and artemisinin. Mol Biochem Parasitol 108: 13-23.
26. Spalding MD, Eyase FL, Akala HM, Bedno SA, Prigge ST, et al. (2010) Increased prevalence of the pfdhfr/pfdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. Malar J 9: 338.
27. Hastings IM, Ward SA, (2005) Coartem (Artemether-lumefantrine) in Africa: the beginning of the end? J Infect Dis 192: 1303-1304.
28. Mungthin M, Khositnithikul R, Sitthichot N, Suwandittakul N, Wattanaveeradej V, et al. (2010) Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum. Am J Trop Med Hyg 83: 1005-1009.
29. Barnes AJ, Ong EL, Dunbar EM, Mandal BK, Wilkins EG, (1991) Failure of chloroquine and proguanil prophylaxis in travellers to Kenya. Lancet 338: 1338-1339.
30. Barnes KI, Little F, Mabuza A, Mngomezulu N, Govere J, et al. (2008) Increases gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. J Infect Dis 197: 1605-1613.
31. Mobula L, Lilley B, Tshefu AK, Rosenthal PJ, (2009) Resistance-mediating polymorphisms in Plasmodium falciparum infections in Kinshasa, Democratic Republic of the Congo. Am J Trop Med Hyg 80: 555-558.
32. Dlamini SV, Beshir K, Sutherland CJ, (2010) Markers of antimalarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolates. Malar J 9: 68.
33. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE, (2011) Intermittent Treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis 53: 224-230.